Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Moein Ala
Endocrinology (2021) Vol. 162, Iss. 12
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 203
Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats
Moein Ala, Mohammad Reza Fallahpour Khoshdel, Ahmad Reza Dehpour
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 50
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets
Yinshuang Chen, Weipeng Wang, Maria P. Morgan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 30
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Daniel Clayton‐Chubb, William Kemp, Ammar Majeed, et al.
Nutrients (2023) Vol. 15, Iss. 3, pp. 687-687
Open Access | Times Cited: 23
The current landscape of antifibrotic therapy across different organs: A systematic approach
Isabel Fuster‐Martínez, Sara Calatayud
Pharmacological Research (2024) Vol. 205, pp. 107245-107245
Open Access | Times Cited: 7
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus
Monika Bhardwaj, Papiya Mitra Mazumder
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 7
Dapagliflozin alleviates renal podocyte pyroptosis via regulation of the HO‑1/NLRP3 axis
Zhenwang Zhang, Ping Ni, Ming-Qiu Tang, et al.
Molecular Medicine Reports (2023) Vol. 28, Iss. 5
Open Access | Times Cited: 13
The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial
Adil Khaliq, Haroon Badshah, Yasar Shah, et al.
Medicine (2024) Vol. 103, Iss. 45, pp. e40356-e40356
Open Access | Times Cited: 5
Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines
Anwesha Gangopadhyay, Radwa Ibrahim, Karli Theberge, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 21
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
Lei Miao, Jing Xu, Giovanni Targher, et al.
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 725-738
Open Access | Times Cited: 19
Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
Tieshan Teng, Shuai Qiu, Yiming Zhao, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 7841-7841
Open Access | Times Cited: 19
New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling
Yang Chen, Daoquan Peng
International Immunopharmacology (2023) Vol. 118, pp. 110072-110072
Open Access | Times Cited: 12
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 6300-6314
Open Access | Times Cited: 4
Empagliflozin rescues lifespan and liver senescence in naturally aged mice
Jiangchuan Long, Ziyu Ren, Yaqian Duan, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4969-4986
Open Access | Times Cited: 4
Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination
Kaijie Ren, Xueni Wang, Rulan Ma, et al.
European Journal of Pharmacology (2024), pp. 177002-177002
Open Access | Times Cited: 4
A critical review on SGLT2 inhibitors for diabetes mellitus, renal health, and cardiovascular conditions
Nitish Kumar, Bimlesh Kumar, Sumel Ashique, et al.
Diabetes Research and Clinical Practice (2025) Vol. 221, pp. 112050-112050
Closed Access
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
В. Т. Ивашкин, О. М. Драпкина, M. V. Maevskaya, et al.
Russian Journal of Gastroenterology Hepatology Coloproctology (2025) Vol. 35, Iss. 1, pp. 94-152
Open Access
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Rong Xu, Difei Lian, Yan Xie, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 7, pp. 134-134
Open Access | Times Cited: 10
ATP Citrate Lyase Supports Cardiac Function and NAD+/NADH Balance And Is Depressed in Human Heart Failure
Mariam Meddeb, Navid Koleini, Seungho Jun, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Molecular mechanism of empagliflozin cardioprotection in 5-fluorouracil (5-FU)-induced cardiotoxicity via modulation of SGLT2 and TNFα/TLR/NF-κB signaling pathway in rats
Marwa M. M. Refaie, Sayed Shehata, Maram El‐Hussieny, et al.
Toxicological Research (2023) Vol. 40, Iss. 1, pp. 139-151
Open Access | Times Cited: 9
Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes
Silvia Giannattasio, Anna Citarella, Sofia Trocchianesi, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 14
Insights into Concomitant Atrial Fibrillation and Chronic Kidney Disease
Yanan Wang, Yi Yang, Fan He
Reviews in Cardiovascular Medicine (2022) Vol. 23, Iss. 3
Open Access | Times Cited: 12
Dapagliflozin: A Promising Strategy to Combat Cisplatin-Induced Hepatotoxicity in Wistar Rats
Shakta Mani Satyam, Laxminarayana Kurady Bairy, Abdul Rehman, et al.
Biology (2024) Vol. 13, Iss. 9, pp. 672-672
Open Access | Times Cited: 2
Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin
Panagiotis Theofilis, Aikaterini Vordoni, Rigas Kalaitzidis
Life (2022) Vol. 12, Iss. 10, pp. 1663-1663
Open Access | Times Cited: 10
Non-alcoholic fatty liver disease is associated with a worse prognosis in patients with heart failure: A pool analysis
Min Qiu, Jiahuan Li, Shali Hao, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top